Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-154 in Polymyalgia Rheumatica Dependent on Glucocorticoid Treatment
jRCT2031210315Phase 2Suspended
- Sponsor
- AbbVie Inc.
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of ABBV-154 in polymyalgia rheumatica (PMR) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Time to Flare. Started Oct 2021; status: suspended.
02
Drugs
ABBV-154
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on jRCT2031210315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210315.